about
MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsismiR-15 and miR-16 induce apoptosis by targeting BCL2A microRNA expression signature of human solid tumors defines cancer gene targetsMicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemiasModulation of mismatch repair and genomic stability by miR-155MiR-15a and miR-16-1 cluster functions in human leukemiaA microRNA signature of hypoxiaAnti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target moleculeMicroRNA gene expression deregulation in human breast cancerMicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocalityTumor suppressor functions of ARLTS1 in lung cancersUltraconserved regions encoding ncRNAs are altered in human leukemias and carcinomasFamilial cancer associated with a polymorphism in ARLTS1Micro-RNA profiling in kidney and bladder cancersExtensive modulation of a set of microRNAs in primary glioblastomaA MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemiaMicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.Non-coding RNAs change their expression profile after Retinoid induced differentiation of the promyelocytic cell line NB4MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.Identification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology.Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment.Micromarkers: miRNAs in cancer diagnosis and prognosis.Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunDAltered miRNA expression in T regulatory cells in course of multiple sclerosis.MicroRNAs dysregulation in human malignant pleural mesothelioma.miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma.MicroRNAs in human cancer: from research to therapy.Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.Mutated beta-catenin evades a microRNA-dependent regulatory loop.MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.MicroRNA expression changes during human leukemic HL-60 cell differentiation induced by 4-hydroxynonenal, a product of lipid peroxidation.MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS).MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.MicroRNA profiling for the identification of cancers with unknown primary tissue-of-originIncrease of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells.Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR.Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.Absolute quantification of cell-free microRNAs in cancer patients
P50
Q21091178-11912CE4-F492-4683-8D0A-5E30DE3E2E3FQ24536069-5A299072-B00B-4040-B694-083D4AEC795BQ24541455-F8037924-E634-4E18-8AB9-63D1AF918CFCQ24564008-7766E88C-62EC-43A0-88BF-117B2B65005DQ24612859-940FDF10-6F51-475D-B2F1-EEC502036BEFQ24647555-7A86C60F-1B26-4E80-9A15-02B027328D08Q24681599-7CD23E3E-4D2E-456A-8C3C-258B0407CCACQ27015933-6F5589B6-6EB0-461F-8A61-ED02F9DA52F9Q27860690-85871299-4E54-44F8-BE6E-2FF4EC8BCEF8Q28115464-5C6E7818-8523-4095-B0F0-668947DEB6E0Q28240843-F89707B3-A68A-4470-A4D8-5B13C01ECE3AQ28244959-AB90A40D-9913-442F-91B9-F2F24D85B5CAQ28246251-82982E90-EA03-4F7D-83E6-5B8D5EB25855Q28247306-24DE6967-F812-4B0C-A3F5-7485466E7486Q28263314-C2FE1F55-C97A-4767-B5A0-96A49A15D9BBQ28279141-E2306838-3922-4529-BA64-F707EE86991DQ30665824-CA1F4FD2-66AE-4F7E-8C35-28F34A9D0A52Q33533928-0D76F130-DDD2-43C9-83D6-34A1223C2A85Q33942272-5BE63376-081E-4A80-AD1F-99C8B1F98DFEQ34078569-A3723AD8-20FE-4B16-ADE6-ACE88EFD7B06Q34103735-6164B10D-B142-4661-AB02-02E9851AECCEQ34108602-6EFFE08C-9440-4ECC-AD6A-4621F1625039Q34125456-3EAF9F86-9FE6-4E00-AFB0-2D3EC71DB70DQ34126437-F441FC33-2316-46C7-86FA-308FF252B6F5Q34167369-BDEFB764-D39D-4E5E-A3F9-DCEACF15DD57Q34248579-D1E56FC4-497E-437C-90B2-045DBF3D1E11Q34599550-AD667D27-22F3-4D93-9BD5-1F41F1237EA4Q34630207-9B763E36-CF25-4D99-AC95-1D1BC9AB98A8Q34647028-1D116C76-1712-4A16-AA16-1E37BA71E3E5Q34720637-570879A2-3102-4D8A-9B91-5E93315A4481Q34784133-DD2C2309-1FCE-4A42-9080-4B39C67F5A79Q34885097-5A820878-FD3B-4838-A229-C193B351BEA6Q34991081-F88426A7-10D6-4DDB-9974-AA8E1581F017Q34997023-B0C6BABF-6442-4507-92A3-49089158C702Q35064852-02580FE6-F9A1-4F81-A1DD-405A97C1FF2BQ35075757-C271056C-0766-4823-8083-AA7F38A3ECFEQ35301892-D67939BA-BFDC-4B2B-8482-27B4EB2C16DDQ35789307-BAA77442-ED56-4B91-BE14-D38EF2EEAC79Q35824254-0C0F5195-9F7C-4C74-B801-6FC1FB105D35Q35987412-D7FE3E37-00FD-4057-B4C8-F1E9BEB58E0A
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Manuela Ferracin
@af
Manuela Ferracin
@an
Manuela Ferracin
@ast
Manuela Ferracin
@bar
Manuela Ferracin
@bm
Manuela Ferracin
@br
Manuela Ferracin
@ca
Manuela Ferracin
@co
Manuela Ferracin
@cs
Manuela Ferracin
@cy
type
label
Manuela Ferracin
@af
Manuela Ferracin
@an
Manuela Ferracin
@ast
Manuela Ferracin
@bar
Manuela Ferracin
@bm
Manuela Ferracin
@br
Manuela Ferracin
@ca
Manuela Ferracin
@co
Manuela Ferracin
@cs
Manuela Ferracin
@cy
prefLabel
Manuela Ferracin
@af
Manuela Ferracin
@an
Manuela Ferracin
@ast
Manuela Ferracin
@bar
Manuela Ferracin
@bm
Manuela Ferracin
@br
Manuela Ferracin
@ca
Manuela Ferracin
@co
Manuela Ferracin
@cs
Manuela Ferracin
@cy
P214
P1053
K-2097-2016
P106
P1153
9045285800
P21
P214
P31
P3829
P396
IT\ICCU\CFIV\260921
P496
0000-0002-1595-6887
P569
1978-01-01T00:00:00Z
P735
P7859
viaf-307339733